Filtered By:
Vaccination: Influenza Vaccine
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 1458 results found since Jan 2013.
Two Are Better Than One: Expanding Our Covid-19 Vaccine Antigens
Like influenza, SARS-CoV-2 is an expert at mutating and evading prior immunity. This includes vaccine-induced immunity. New research suggests that expanding the target area of our vaccines to include the virus' nucleocapsid protein may offer stronger and broader protection.
Source: Forbes.com Healthcare News - October 3, 2022 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation Coronavirus business pharma & Source Type: news
Az influenza mint kardiol ógiai rizikótényező és a vakcináció szerepe a kockázat csökkentésében
Orv Hetil. 2022 Oct 2;163(40):1585-1596. doi: 10.1556/650.2022.32597. Print 2022 Oct 2.ABSTRACTThe different types of cardiovascular diseases, including coronary heart disease, cardiac arrhythmias and heart failure are highly prevalent in the society. Cardiovascular diseases are the leading cause of mortality. Although the influenza is forced out from the mainstream of thinking nowadays because of the ongoing SARS-CoV-2 pandemic, it still has its serious epidemiological significance. The seasonal influenza epidemic often contributes to mortality mainly, but not exclusively among old, multi-morbid patients. There are a vast...
Source: Orvosi Hetilap - October 2, 2022 Category: General Medicine Authors: Zsolt K örömi Gergely Gy örgy Nagy Source Type: research
TWiV 931: Clinical update with Dr. Daniel Griffin
In his weekly clinical update Dr. Griffin discusses increased acute respiratory illnesses among children and adolescents, estimates of monkeypox incubation period, generation time, and reproduction number, rapid increase in suspected SARS-CoV-2 reinfections, interim infection prevention and control recommendations for healthcare personnel during COVID-19, SARS-CoV-2 secondary attack rates in vaccinated and unvaccinated household contacts during replacement of delta with omicron variant, breakthrough infection by SARS-CoV-2 delta and omicron variants elicited immune response comparable to mRNA booster vaccination, inter...
Source: virology blog - October 1, 2022 Category: Virology Authors: Vincent Racaniello Tags: This Week in Virology antiviral coronavirus COVID-19 delta inflammation influenza Long Covid marburg virus monkeypox monoclonal antibody Omicron pandemic poliovirus SARS-CoV-2 vaccine vaccine booster variant of concern Source Type: blogs
Big COVID-19 waves may be coming, new Omicron strains suggest
Nearly 3 years into the pandemic, SARS-CoV-2 faces a formidable challenge: finding new ways around the immunity humans have built up through vaccines and countless infections. Worrisome new data show it is up to the challenge. Several new and highly immune-evasive strains of the virus have caught scientists’ attention in recent weeks; one or more may well cause big, new COVID-19 waves this fall and winter.
“We can say with certainty that something is coming. Probably multiple things are coming,” says Cornelius Roemer, who studies viral evolution at the University of Basel. Whether they will also lead to many hos...
Source: ScienceNOW - September 27, 2022 Category: Science Source Type: news
Seroprevalence of influenza viruses in Shandong, Northern China during the COVID-19 pandemic
Front Med. 2022 Sep 24. doi: 10.1007/s11684-022-0930-5. Online ahead of print.ABSTRACTNonpharmaceutical interventions (NPIs) have been commonly deployed to prevent and control the spread of the coronavirus disease 2019 (COVID-19), resulting in a worldwide decline in influenza prevalence. However, the influenza risk in China warrants cautious assessment. We conducted a cross-sectional, seroepidemiological study in Shandong Province, Northern China in mid-2021. Hemagglutination inhibition was performed to test antibodies against four influenza vaccine strains. A combination of descriptive and meta-analyses was adopted to com...
Source: Cancer Control - September 24, 2022 Category: Cancer & Oncology Authors: Chuansong Quan Zhenjie Zhang Guoyong Ding Fengwei Sun Hengxia Zhao Qinghua Liu Chuanmin Ma Jing Wang Liang Wang Wenbo Zhao Jinjie He Yu Wang Qian He Michael J Carr Dayan Wang Qiang Xiao Weifeng Shi Source Type: research
TWiV 938: Clinical update with Dr. Daniel Griffin
In his weekly clinical update Dr. Griffin reviews the public health response to poliovirus in New York, impact of mandatory influenza vaccination, monkeypox in a young infant, health care worker exposure to monkeypox virus, monkeypox testing delays, transmission potential of monkeypox virus, TPOXX trial for monkeypox, detection of SARS-CoV-2 subgenomic mRNA, mucosal IgA against SARS-CoV-2, BNT262b2 against Omicron, awareness and use of SARS-CoV-2 antivirals, comparable outcomes for Bebtelovimab and Nirmatrelvir, and COVID-19 and Alzheimer's disease.
Source: virology blog - September 24, 2022 Category: Virology Authors: Vincent Racaniello Tags: This Week in Virology antiviral coronavirus COVID-19 delta inflammation influenza Long Covid marburg virus monkeypox monoclonal antibody Omicron pandemic poliovirus SARS-CoV-2 vaccine vaccine booster variant of concern Source Type: blogs
Seroprevalence of influenza viruses in Shandong, Northern China during the COVID-19 pandemic
AbstractNonpharmaceutical interventions (NPIs) have been commonly deployed to prevent and control the spread of the coronavirus disease 2019 (COVID-19), resulting in a worldwide decline in influenza prevalence. However, the influenza risk in China warrants cautious assessment. We conducted a cross-sectional, seroepidemiological study in Shandong Province, Northern China in mid-2021. Hemagglutination inhibition was performed to test antibodies against four influenza vaccine strains. A combination of descriptive and meta-analyses was adopted to compare the seroprevalence of influenza antibodies before and during the COVID-19...
Source: Frontiers of Medicine - September 24, 2022 Category: General Medicine Source Type: research
Plant-derived immuno-adjuvants in vaccines formulation: a promising avenue for improving vaccines efficacy against SARS-CoV-2 virus
Pharmacol Rep. 2022 Sep 20. doi: 10.1007/s43440-022-00418-4. Online ahead of print.ABSTRACTThe SARS-CoV-2 outbreak has posed a plethora of problems for the global healthcare system and socioeconomic burden. Despite valiant efforts to contain the COVID-19 outbreak, the situation has deteriorated to the point that there are no viable preventive therapies to treat this disease. The case count has skyrocketed globally due to the newly evolved variants. Despite vaccination drives, the re-occurrence of recent pandemic waves has reinforced the importance of innovation/utilization of immune-booster to achieve appropriate long-term...
Source: Pharmacological Reports - September 20, 2022 Category: Drugs & Pharmacology Authors: Arbind Kumar Aashish Sharma Narendra Vijay Tirpude Yogendra Padwad Vipin Hallan Sanjay Kumar Source Type: research
mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations
In this study, we determined if any of the components of mRNA-1273 or BNT162b2 formulations elicited PEG-specific antibody responses in serum by enzyme linked immunosorbent assay (ELISA). We detected an increase in the reactivity to mRNA vaccine formulations in mRNA-1273 but not BNT162b2 vaccinees' sera in a prime-boost dependent manner. Furthermore, we observed the same pattern of reactivity against irrelevant lipid nanoparticles from an influenza virus mRNA formulation and found that the reactivity of such antibodies correlated well with antibody levels against high and low molecular weight PEG. Using sera from participa...
Source: Vaccine - September 17, 2022 Category: Allergy & Immunology Authors: Juan Manuel Carre ño Gagandeep Singh Johnstone Tcheou Komal Srivastava Charles Gleason Hiromi Muramatsu Parnavi Desai Judith A Aberg Rachel L Miller Paris Study Group Norbert Pardi Viviana Simon Florian Krammer Source Type: research
Influenza vaccine and subsequent development of zoster
CONCLUSIONS: There was a slight increase in risk of HZ in people receiving influenza vaccine in the first 1-15 days after vaccination.PMID:36114790 | DOI:10.1111/irv.13055
Source: Respiratory Care - September 17, 2022 Category: Respiratory Medicine Authors: Kai-Che Wei Yu-Chia Chang Yu-Tung Huang Source Type: research
